Literature DB >> 11478490

Selection of HCV NS5A quasispecies during IFN therapy in patients with chronic HCV.

M Paterson1, C Laxton, R D Goldin, A M Ackrill, G R Foster.   

Abstract

Interferon treatment of chronic hepatitis C virus infection is successful in a minority of patients. The sequence of the interferon sensitivity determining region (ISDR) of the NS5A protein may determine the outcome of therapy in patients infected with HCV genotype 1. To determine whether IFN treatment caused selection of ISDR quasispecies and whether sequences bearing the putative IFN-resistance motif (HCV-J sequence) were selected, we examined amino acid changes in the ISDR in patients with HCV of different genotypes with and without therapy. We found that the ISDR sequence was highly variable and variability was greatest in patients with HCV of genotype 1. IFN treatment was found to exert a selection pressure on ISDR quasispecies, but the putative interferon-resistant variant was not enriched in patients of any genotype. Hence factors other than the sequence of the ISDR region played a role in the IFN resistance of these patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11478490     DOI: 10.1023/a:1010623417345

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  19 in total

1.  The interferon sensitivity determining region: all hepatitis C virus isolates are not the same.

Authors:  D Herion; J H Hoofnagle
Journal:  Hepatology       Date:  1997-03       Impact factor: 17.425

2.  The NS5A protein of hepatitis C virus partially inhibits the antiviral activity of interferon.

Authors:  J Song; M Fujii; F Wang; M Itoh; H Hotta
Journal:  J Gen Virol       Date:  1999-04       Impact factor: 3.891

3.  Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium.

Authors: 
Journal:  J Viral Hepat       Date:  1999-01       Impact factor: 3.728

4.  Response to interferon-alpha of Egyptian patients infected with hepatitis C virus genotype 4.

Authors:  A el-Zayadi; P Simmonds; H Dabbous; L Prescott; O Selim; A Ahdy
Journal:  J Viral Hepat       Date:  1996-09       Impact factor: 3.728

5.  Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution.

Authors:  M Martell; J I Esteban; J Quer; J Genescà; A Weiner; R Esteban; J Guardia; J Gómez
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

6.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

7.  Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication.

Authors:  S J Polyak; D M Paschal; S McArdle; M J Gale; D Moradpour; D R Gretch
Journal:  Hepatology       Date:  1999-04       Impact factor: 17.425

8.  The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus.

Authors:  J C Sáiz; F X López-Labrador; S Ampurdanés; J Dopazo; X Forns; J M Sánchez-Tapias; J Rodés
Journal:  J Infect Dis       Date:  1998-04       Impact factor: 5.226

9.  Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein.

Authors:  M J Gale; M J Korth; N M Tang; S L Tan; D A Hopkins; T E Dever; S J Polyak; D R Gretch; M G Katze
Journal:  Virology       Date:  1997-04-14       Impact factor: 3.616

Review 10.  Variability of hepatitis C virus.

Authors:  P Simmonds
Journal:  Hepatology       Date:  1995-02       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.